

Central and peripheral nervous system involvement by COVID-19: A systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings

Juan I. Guerrero

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0001-8750-6554>

Luis A. Barragán

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0003-3197-5671>

Juan D. Martínez

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0002-3042-7633>

Juan P. Montoya

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0001-9722-4550>

Alejandra Peña

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0002-3679-9411>

Fidel E. Sobrino

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0001-8334-6215>

Zulma Tovar-Spinoza

Upstate University Hospital <https://orcid.org/0000-0002-5275-7502>

Kemel A. Ghotme (✉ kemelgg@unisabana.edu.co)

Translational Neuroscience Research Lab Universidad de La Sabana <https://orcid.org/0000-0001-6802-4373>

Systematic Review

Keywords: Central and peripheral nervous system, SARS-CoV-2, COVID-19, pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, cerebrospinal fluid findings

DOI: <https://doi.org/10.21203/rs.3.rs-105950/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: SARS-CoV-2 can affect the human brain and other neurological structures. An increasing number of publications report neurological manifestations in patients with COVID-19. However, no studies have comprehensively reviewed the clinical and paraclinical characteristics of the central and peripheral nervous system's involvement in these patients. This study aimed to describe the features of the central and peripheral nervous system involvement by COVID-19 in terms of pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings.

Methods: We conducted a comprehensive systematic review of all the original studies reporting patients with neurological involvement by COVID-19, from December 2019 to June 2020, without language restriction. We excluded studies with animal subjects, studies not related to the nervous system, and opinion articles. Data analysis combined descriptive measures, frequency measures, central tendency measures, and dispersion measures for all studies reporting neurological conditions and abnormal ancillary tests in patients with confirmed COVID-19.

Results: A total of 143 observational and descriptive studies reported central and peripheral nervous system involvement by COVID-19 in 10723 patients. Fifty-one studies described pathophysiologic mechanisms of neurological involvement by COVID-19, 119 focused on clinical manifestations, 4 described neuropathology findings, 62 described neuroimaging findings, 28 electrophysiology findings, and 60 studies reported cerebrospinal fluid results. The reviewed studies reflect a significant prevalence of the nervous system's involvement in patients with COVID-19, ranging from 22.5% to 36.4% among different studies, without mortality rates explicitly associated with neurological involvement by SARS-COV-2. We thoroughly describe the clinical and paraclinical characteristics of neurological involvement in these patients.

Conclusions: Our evidence synthesis led to a categorical analysis of the central and peripheral involvement by COVID-19 and provided a comprehensive explanation of the reported pathophysiological mechanisms by which SARS-CoV-2 infection may cause neurological impairment. International collaborative efforts and exhaustive neurological registries will enhance the translational knowledge of COVID-19's CNS and PNS involvement and generate strategies for therapeutic decision-making.

Registration: This review is registered in PROSPERO (CRD42020193140), July 24, 2020.

Background

In the first nine months of 2020, infections by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) affected more than 32 million people around the world, and coronavirus disease 2019 (COVID-19) caused more than one million deaths [1], leading to one of the most devastating pandemics declared by the World Health Organization in the 21st Century [2]. SARS-CoV-2 is a 29,903 bp single-stranded RNA encapsulated virus from the Coronaviridae family, betacoronavirus subfamily, capable of affecting the human brain and other structures of the nervous system [2–4].

An increasing number of publications report abnormalities of central and peripheral nervous systems in patients with severe and non-severe COVID-19 [5–8]. Several studies, including systematic reviews, have reported

neurological manifestations of COVID-19 and different abnormal findings in ancillary tests. However, no studies in the first months of pandemics have comprehensively reviewed the clinical and paraclinical characteristics of the involvement of the central nervous system (CNS) and peripheral nervous system (PNS) in patients affected by this infectious disease.

The purpose of this systematic review is to describe the characteristics of the central and peripheral nervous system involvement by COVID-19 in terms of its pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid (CSF) findings. This study's results may help clinicians and researchers approach patients with this condition and generate new inquiries with implications for practice. The explicit questions addressed were: What are the characteristics of the central and peripheral nervous system involvement by COVID-19? What is the described pathophysiology of central and peripheral nervous system involvement by COVID-19? What are the clinical manifestations of central and peripheral nervous system involvement by COVID-19? What are the neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings in patients with central and peripheral nervous system involvement by COVID-19?

Methods

We conducted a comprehensive systematic review of all the original studies reporting patients with neurological involvement by COVID-19. We followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [9, 10]. This review is registered in PROSPERO (CRD42020193140) on July 24, 2020.

Eligibility criteria

We included all original studies, including cohort, case-control, time series, case series, case reports, and letters to the editor containing full description of human subjects with confirmed SARS-CoV-2 infection and any indication of CNS or PNS involvement. We set the timeframe between December 2019 and June 2020, without language restriction. We excluded studies with animal subjects, studies not related to the nervous system involvement of SARS-CoV-2, publications about coronaviruses other than SARS CoV-2, reports of individuals with suspected or not confirmed infection by SARS-CoV-2, and opinion articles.

Data source

We conducted a systematic search in PubMed/MEDLINE, Scopus, Cochrane Library, LILACS, and SciELO databases from June 4 to June 30, 2020, using the MeSH terms: ("COVID-19" OR "Coronavirus" OR "severe acute respiratory syndrome coronavirus 2") AND ("Central Nervous System" OR "Peripheral Nervous System"). We added additional terms for amplifying the scope of the review, namely: "CSF", "Cerebrospinal fluid", "brain AND spine imaging", "neuropathology", "peripheral neuropathy", and "seizures" and sought for individual patient-level data and summary estimates.

Data extraction

Five reviewers simultaneously screened titles, abstracts, and keywords to check for the fulfillment of inclusion and exclusion criteria. The authors reviewed the resulting articles independently in full text and hand-searched each article's reference lists to ensure literature saturation. From the resulting studies, we extracted the name of first author, title, year of publication, journal, country, study design, peripheral or central nervous system involvement,

and discussed topics (physiopathology, clinical manifestations, neuropathology, neuroradiology, electrophysiology studies or cerebrospinal fluid findings). We performed a quality assessment at the study level. For case reports and case series, we applied the CARE checklist. Since most of the studies were observational or descriptive, aspects of internal validity such as randomization, treatment allocation, or blinding were not applicable. We assessed external validity and generalizability aspects. All reviewers participated in the quality assessment and resolved disagreements by consensus. The data extracted were processed in Excel spreadsheets and categorized into pathophysiology, clinical features, neuropathology, neuroimaging, electrophysiology, and CSF abnormalities.

Evidence synthesis and data analysis

We performed an evidence synthesis taking into account all selected studies, using a deductive method. Three senior reviewers checked the received data from the selected studies. All authors made decisions and resolved disagreements between individual judgments by consensus. Data analysis combined descriptive measures, frequency measures, central tendency measures, and dispersion measures for all studies reporting neurological conditions and abnormal ancillary tests in patients with confirmed COVID-19.

Results

This review yielded 143 original publications reporting CNS and PNS involvement by COVID-19, with the selected characteristics, alone or combined (see Figure 1).

The included studies were essentially observational and descriptive. From the total, 119 focus on clinical manifestations, 62 describe neuroimaging findings, 60 studies report cerebrospinal fluid results, 51 describe pathophysiologic mechanisms of CNS and PNS involvement by COVID-19, 28 report electrophysiology findings, and four describe neuropathology findings. Among all studies reviewed, we found a total of 10723 patients with a confirmed diagnosis of COVID-19 who displayed features compatible with neurological involvement. Among them, we found 1633 patients with specific nosological entities or clinical conditions affecting the central nervous system and 43 the peripheral nervous system (Table 1). The remaining 9047 patients reportedly presented with one or more neurological signs and symptoms not attributed to a specific clinical condition or nosological entity.

Table 1. Neurological conditions associated with COVID-19.

Clinical conditions associated with COVID-19 affecting the central nervous system	No. of patients / Proportion
Encephalopathy	990 (60·7%)
Unspecified stroke type	416 (25·5%)
Ischemic stroke	159 (9·7%)
Hemorrhagic stroke	40 (2·4%)
Encephalitis and meningoencephalitis	19 (1·2%)
Acute disseminated encephalomyelitis (ADEM)	4 (0·2%)
Venous sinus thrombosis	3 (0·2%)
Multiple sclerosis exacerbation	2 (0·1%)
Total	1633 (100%)
Clinical conditions associated with COVID-19 affecting the peripheral nervous system	No. of patients / Proportion
Guillain-Barre syndrome	22 (51·2%)
Other cranial nerve disorders	12 (27·9%)
Facial palsy (Bell syndrome)	5 (11·6%)
Miller-Fisher syndrome and polyneuritis cranialis	4 (9·3%)
Total	43 (100%)

A total of 8885 (86,3%) reports of neurological signs and symptoms were related to CNS (Table 2), while 1414 (13,7%) were related to PNS (Table 3).

Table 2. Distribution of signs and symptoms indicating central nervous system involvement in patients with COVID-19

Signs and symptoms indicating central nervous system involvement	No. of patients / Proportion
Diffuse compromise	8129 (91·5%)
Psychiatric symptoms (including anxiety disorders, mood disorders, psychosis, and insomnia)	4981
Headache	1805
Dizziness	527
Consciousness impairment	416
Delirium	340
Nausea/vomiting	16
Nuchal Rigidity	4
Non-specific combination of signs and symptoms	40
Focal deficit	410 (4·6%)
Extrapyramidal disorders	279
Corticospinal tract impairment	61
Ataxia	18
Dysarthria	13
Amnesia	12
Aphasia	7
Monoparesis	6
Central facial weakness	5
Myoclonus	5
Homonymous hemianopia	4
Seizures	346 (3·9%)
Non-specified seizures	324
Generalized seizures	9
Non-convulsive status epilepticus	6
Focal seizures	3
Seizure-like events (abnormal involuntary movements)	3
Non-epileptic convulsive syncope	1
Total patients with CNS signs and symptoms	8885 (100%)

Table 3. Distribution of signs and symptoms indicating peripheral nervous system involvement in patients with COVID-19.

Signs and symptoms indicating peripheral nervous system involvement	No. of patients / Proportion
Smell/taste impairment	746 (52.8%)
Anosmia + Ageusia	477
Anosmia/hyposmia	128
Ageusia/dysgeusia	141
Visual impairment	9 (0.6%)
Unspecified decreased visual acuity	8
Complete visual loss	1
Oculomotor impairment	14 (1%)
Ophthalmoparesis	7
Diplopia	3
Anisocoria	1
Bilateral mydriasis	1
Bilateral Abducens Palsy	1
Unilateral Abducens Palsy	1
Facial palsy	13 (0.9%)
Bilateral weakness/diplegia	7
Unilateral	6
Other cranial nerve impairment	32 (2.3%)
Glossopharyngeal neuralgia	9
Trigeminal neuralgia	8
Tinnitus	5
Decreased hearing	5
Vasoglossopharyngeal neuralgia	2
Dysphagia	2
Reduced tongue movements/tongue deviation	1
Peripheral neuropathies involving trunk and limbs	353 (24.9%)
Mixed neuropathy	247
Pure sensitive impairment	31
Paresthesia	30
Hypoesthesia	1
Pure motor impairment	40

Areflexia	14
Distal weakness	8
Tetraparesis	7
Gait difficulties/instability	6
Paraparesis	3
Tetraplegia	1
Paraplegia	1
Neuralgia	8
Limb neuralgia	7
Occipital neuralgia	1
Dysautonomia manifestations	27
Nerve roots and plexus disorders	145 (10·3%)
Myopathic involvement	102 (7·2%)
Total patients with PNS signs and symptoms	1414 (100%)

Figure 2 summarizes the main neuroimaging findings associated with COVID-19, while Table 4 represents the main CSF findings. Most of the included studies did not report mortality rates explicitly associated with neurological involvement by SARS-COV-2.

Table 4. Cerebrospinal fluid (CSF) findings in patients with COVID-19 and different neurological conditions

Cerebrospinal fluid findings in patients with central nervous system involvement by SARS-CoV2								
Clinical manifestation	N° patients	Proteins (mg/dL)		Cells (cells/ μ L)		SARS-CoV-2 PCR		
		Average	Range	Average	Range	Positive	Negative	N/M
Encephalopathy	13	67.3	0 to 230	9.8	0 to 37	0	9	4
Encephalitis	7	83.1	19 to 200	40.6	0 to 115	2	5	0
Demyelinating lesions in brain and spine	4	47	32 to 62	1	1	1	1	2
Meningoencephalitis	3	463.5	461 to 466	17.3	0 to 21	1	2	0
Stroke	3	50	50	0	0	0	2	1
Seizures	3	66	66	3	1 to 5	0	3	0
Brain vasculopathies	2	292.5	78 to 507	6.5	0 to 13	0	2	0
Rhombencephalitis	1	42.3	42.3	0	0	0	0	1
Maniac episode	1	190	190	0	0	0	1	0
Total	37					4	25	8
Cerebrospinal fluid findings in patients with peripheral nervous system involvement by SARS-CoV2								
Clinical manifestation	N° patients	Proteins (mg/dL)		Cells (cells/ μ L)		SARS-CoV-2 PCR		
		Average	Range	Average	Range	Positive	Negative	N/M
Guillain-Barré syndrome	17	105.9	40 to 193	2.4	0 to 9	0	11	6
Miller-Fisher syndrome	2	75	62 to 80	2.5	0 to 5	0	1	1
Polineuritis cranealis	1	62	62	2	2	0	1	0
Facial palsy	2	44	44	0	0	0	2	0
Total	22					0	15	7

CSF glucose levels were normal or slightly increased in all reports. Cell differential showed lymphocytic predominance in all reports. *N/M: Not measured. CNS: Central nervous system. PCR: Polymerase chain reaction. CSF: Cerebrospinal fluid.*

The reviewed studies reflect a significant prevalence of nervous system' involvement in patients with COVID-19. Neurological manifestations appear in a range of 22.5% to 36.4% of all COVID-19 patients among different studies

[6, 11–14]. We classified them in diffuse and focal CNS signs and symptoms, seizures, cranial nerve impairment, encephalopathy, neuroinflammatory disorders, acute cerebrovascular disease, and peripheral neuropathies.

Diffuse CNS signs and symptoms

Fifty-three studies reported 8129 diffuse signs and symptoms of CNS involvement by COVID-19, including neuropsychiatric disorders (61.3%), headache (22.2%), dizziness (6.6%), consciousness impairment (5.2%), delirium (4.3%), nausea/vomiting (0.3%), and nuchal rigidity (0.1%). Psychiatric symptoms included anxiety, mood disorders, psychosis, insomnia, and others. These symptoms are described in depth in other studies [11, 15, 16] and are not the focus of this review. Headache is, indeed, one of the most common neurological manifestations of SARS-CoV-2 infection, with a variability range of 8 to 39% of cases [13, 17]. Headache can be a primary process in these patients or part of a broad spectrum of neurological syndromes such as meningitis, encephalitis, vasculitis, elevated intracranial pressure, and other clinical conditions associated with COVID-19's neuroinflammatory mechanisms and other underlying systemic causes [7]. Impairment of consciousness and arousal is another common neurological disturbance, documented in up to 37% of patients with COVID-19 as a manifestation of encephalopathy [6, 7]. Delirium was present in 20 to 65% of patients with SARS-CoV-2 infection [18]. It can be attributed directly to SARS-CoV-2 invasive mechanisms to the CNS, leading to a neuroinflammatory response or a multifactorial compromise secondary to sedative therapies, mechanical ventilation, and environmental factors, including social isolation [15]. On the other hand, delirium in critically ill patients with COVID-19 may be a prodromal symptom of infection and hypoxia secondary to severe respiratory failure [15] or an isolated manifestation of COVID-19 [19]. Delirium can also overlap an underlying cognitive impairment, which generates a baseline vulnerability state. However, the elevation of inflammatory markers indicates a concomitant immune response as a precipitant [18]. Furthermore, a history of delirium can increase the risk of post-intensive care syndrome, including cognitive impairment, mental state disorders (such as depression, anxiety, and post-traumatic stress disorder), and physical impairment after leaving the intensive care unit [15]. Dizziness is also a prevalent neurological manifestation, ranging between 7 and 9.4% of patients admitted to intensive care units [20] and 26.21% in general series [6, 17]. Nausea and vomiting are also common neurologic manifestations, with an estimated prevalence of 5% [4]. Their presence may be related to an impairment in the CNS structures related to emesis control in the dorsal vagal complex in the medulla oblongata caused by SARS-CoV-2 [21].

Focal CNS signs and symptoms

Twenty-eight studies reported 410 patients with focal neurological disturbances, including corticospinal and corticobulbar tract impairment, ataxia, dysarthria, amnesia, aphasia, retrochiasmatic visual field alterations, and extrapyramidal disorders. Most of these disturbances were associated with stroke in patients with COVID-19 and are discussed below in this article.

Seizures

Twenty-eight studies reported seizures in 346 patients with COVID-19. Most reports did not specify the seizure type in 324 patients, while a few studies documented generalized or focal seizures [22–30], focal or diffuse non-convulsive status epilepticus [31], seizure-like motor events [22], and non-epileptic convulsive syncope [32] (Table 2). Although COVID-19 patients may present seizures due to hypoxia, metabolic derangements, organ failure, or cerebral damage [33], SARS-CoV-2 systemic infection per se represents a minimal risk for seizures during acute illness [34]. In a retrospective multicentric study aiming to evaluate the incidence and risk of acute symptomatic seizures in 304 patients without a prior history of epilepsy, there were no new-onset seizures or status epilepticus

during the acute phase of COVID-19 [34]. The association between seizures and the severity of COVID-19 remains a matter of debate with evidence in favor [23] and against [35]. There was a previous history of cognitive impairment, older age, and higher levels of creatine-kinase and C-reactive protein after admission for COVID-19 [35] for many patients with seizures. For patients with baseline epilepsy, SARS-CoV-2 infection may trigger seizures; therefore, it is ideal to anticipate breakthrough seizures and prescribe short-term antiseizure medications opportunistically [7]. Continuous electroencephalography (EEG) monitoring in any patient with a critical medical condition who has changed in mental status facilitates the timely diagnosis of non-convulsive status epilepticus [14].

Cranial nerve impairment

Thirty studies reported cranial nerve impairments in patients with COVID-19. Markedly, 746 patients presented smell/taste impairment. Anosmia and dysgeusia/parageusia indicate early involvement of the PNS by SARS-CoV-2, allowing for early screening and isolation of suspected cases before the onset of respiratory symptoms. The neurotrophic properties of SARS-CoV-2 may facilitate access to the CNS through the olfactory nerve and explain why many patients have reported anosmia as a preceding symptom [36]. In COVID-19, the sudden olfactory loss is typically unrelated to nasal swelling or rhinitis [7, 37]. The prevalence of anosmia and ageusia ranges widely from 5% in a study of patients hospitalized in Wuhan to 88% of patients for a cohort study conducted in Germany [7, 12, 37]. Visual deficits reported in COVID-19 include hemianopia in patients with acute ischemic stroke [26, 38, 39] and optic neuritis with acute visual loss [35], associated with optic nerve contrast enhancement in magnetic resonance imaging (MRI). Oculomotor impairment was present in 14 patients, in isolation or as part of a Miller-Fisher syndrome [40, 41]. These patients presented with a compromise of the III, IV, and VI cranial nerves leading to ophthalmoparesis and diplopia. Uni or bilateral abducens' involvement associated with COVID-19 has been described [41, 42]. MRI studies confirmed nerve enhancement in some of them [43, 44]. Facial nerve compromise by SARS-CoV-2 can occur in isolation [45] or as part of peripheral neuropathy like Guillain-Barre syndrome (GBS) [46]. A group of patients presented with bilateral facial diplegia with unresponsive blink reflex or unilateral facial nerve palsy, around ten days of SARS-CoV-2 infection [45, 46]. Usual MRI findings in these patients included facial nerve contrast enhancement [43]. Similarly, in some patients with GBS and cranial nerve impairment, III, VI, VII, and VIII contrast enhancement in MRI was evident [44]. Finally, some authors reported compromise of low cranial nerves among patients with COVID-19, including dysphagia as part of GBS [47], isolated dysphagia [48], and hypoglossal deficit due to rhombencephalitis [49].

Encephalopathy

In this review, 990 patients in 19 studies presented features compatible with acute encephalopathy. Encephalopathy may appear as the predominant disorder at the initial presentation of COVID-19, although most cases rarely progress to severe encephalopathy [27]. Many patients with a clinical diagnosis of encephalopathy had no findings on brain imaging. Transmission electron microscopy studies performed postmortem in patients with acute encephalopathy revealed viral particles within cytoplasmic vacuoles of brain capillary endothelial cells in frontal lobe sections. Reverse transcription polymerase chain reaction (RT-PCR) testing of frozen tissue confirmed the presence of SARS-CoV-2 in the brain [50]. The frontal lobe compromise could explain the behavioral changes seen in some patients, and the viral particles in endothelial cells may support a hematogenous dissemination pathway on SARS-CoV-2 into the CNS. Four patients with confirmed COVID-19 presented acute hemorrhagic necrotizing encephalopathy, with findings associated with disrupting mechanisms of the blood-brain barrier that could be related to cytokine storm [25, 51, 52]. Four additional patients presented clinical and imaging features of posterior reversible encephalopathy syndrome (PRES), with acute onset of headache, altered mental

status, seizures, and visual disturbances accompanied by fluctuations of blood pressure, with hemorrhagic complications [35, 53]. A multifactorial series of mechanisms related to SARS-CoV-2 infection, along with a breakdown of the blood-brain barrier, may contribute to PRES development in susceptible patients. EEG findings in several patients with acute encephalopathy in our review included diffuse or focal (frontal or frontotemporal) slow activity wave patterns and some rhythmic discharges [23, 27, 35, 54–57].

Neuroinflammatory disorders

In our review, 23 patients (in 17 studies) had confirmed CNS inflammatory lesions, including encephalitis, meningoencephalitis, and encephalomyelitis, with variable prevalence [5, 25, 35, 36]. In a cohort of 2660 hospitalized COVID-19 patients, six patients presented with encephalitis as the first and only disorder, two with fatal outcomes [5]. In another cohort of 841 patients, only one patient had confirmed encephalitis [35]. The CSF of patients with inflammatory lesions showed elevated proteins, with an average of 196.3 mg/dl (range of 19-466 mg/dl) and increased cellularity, with 28.95 cells/ μ L (range 0-115 cell/ μ L). Most of these patients had normal glucose levels on CSF, although four patients had slightly increased CSF/Serum glucose ratio [25, 26, 58]. The isolation of SARS-CoV-2 was possible only in three CSF samples [29, 59, 60]. Several authors reported that CSF cellularity was predominantly lymphocytic [26, 29, 58, 61], reaching 100% lymphocytes in one case [60]. Proinflammatory cytokines in CSF measured in six patients showed high levels of interleukin (IL) 6-8, IP-10, monocyte chemoattractant protein-1 (MCP-1), neurofilament light polypeptide (NFL), glial fibrillary acidic protein (GFAP), tumor necrosis factor-alpha (TNF- α), and B-2 microglobulin [55, 58, 61, 62]. CSF samples of 20 patients with CNS compromise, and four with PNS involvement, ruled out concomitant or alternative infections. Ischemic neuronal damage, demyelination, and viral RNA in and around the hippocampus allowed the confirmation of encephalopathy in a patient who underwent brain biopsy [63]. Other neuropathology findings included perivascular lymphocytes and focal leptomeningeal inflammation. Immunohistochemical analysis showed no cytoplasmic viral staining. Brain sections from five different patients expressed low levels of the virus, but positive tests could be explained by in situ virions or bloodstream viral RNA [64]. EEG studies in patients with neuroinflammatory disorders showed generalized slow-wave activity patterns. [60, 61, 65].

Acute cerebrovascular disease

Twenty studies reported 615 patients with acute stroke. Among COVID-19 patients, the reported prevalence of acute ischemic stroke ranged between 1.1 to 2.5%, increasing to 11 to 31% among those with neurological compromise. The mean time of stroke occurrence was ten days after the onset of COVID-19 symptoms, although other studies reported an occurrence as early as two days after clinical onset [66]. Thromboembolic events were the most common neuroimaging finding associated with COVID-19 in this review, including 184 events of acute ischemic strokes. Most of the cases had atypical characteristics, such as multiple arterial territories affected without an identified cardioembolic source, bilateral compromise, a high proportion of vertebrobasilar stroke, arterial dissection, and vasculitis [35, 67, 68]. Most patients presenting COVID-19 associated stroke had baseline cardiovascular risk conditions such as hypertension, diabetes mellitus, hyperlipidemia, smoking, or previous stroke history [13]. In neuropathology findings of selected cases, a few microscopic cortical infarcts were apparent, and the neocortex. Hippocampus and cerebellum had scattered necrotic neurons, indicating terminal hypoxic-anoxic injury. Regional infarcts, however, were not present in the brain, brainstem, or spinal cord. T cells were present surrounding blood vessels and lesions, contrasting with no B cell activation. These non-specific findings can be due to vascular impairment, inflammatory/demyelinating processes, or a combination of mechanisms with direct endothelial cells damage and excessive cytokines release. [69]. For hemorrhagic stroke, the estimated prevalence

ranged between 0.4 to 2.4%. In this review, 40 patients presented hemorrhagic stroke, 66.5% of which were on anticoagulation therapy [70], and one patient reportedly had a ruptured aneurysm [71]. The fact that SARS-CoV-2 binds explicitly to ACE2 receptors, along with thrombocytopenia observed in severe cases, may lead to an increased risk of a cerebral hemorrhage [13]. Postmortem examinations of selected cases revealed mild brain swelling and foci of white matter hemorrhagic lesions central fibrin with associated extravasated red blood cells, with surrounding reactive gliosis. All lesions presented macrophages at the periphery, axonal damage, and myelin loss. In patients with stroke, CSF studies showed an average protein level of 50 mg/dL; SARS-CoV-2 in CSF was positive in only one case [24, 71]. EEG findings in patients with acute stroke were described only for two patients in one study, one of them demonstrated bilateral slowing of the background rhythm with sharp frontal waves, and the other one showed persistence of sharp slow waves, mainly over the left-hemispheric regions [24].

Peripheral neuropathies

Fifteen studies reported 22 patients infected with SARS-CoV-2 and GBS, while three studies reported three patients with Miller-Fisher syndrome and one patient with polyneuritis cranialis [40, 41, 72]. The prevalence of GBS accounted for approximately 0.5% of COVID-19 patients, who developed the clinical features between five to ten days after the acute onset of respiratory symptoms [45, 73]. Whittaker et al. suggested that GBS could be a significant neurological sequela of SARS-CoV-2 [12], whereas other authors imply that GBS may occur in patients with COVID-19 without any preceding respiratory or systemic symptoms [47]. Most case reports describe patients presenting with marked lower limb weakness over upper limbs and areflexia that occurred acutely or subacutely. Variable sensory abnormalities have also been described [12]. Nerve conduction and electromyography studies carried out in 16 patients with GBS and COVID-19 reported acute inflammatory demyelinating polyneuropathy in 12 cases [44, 47, 73–80], sensory-motor axonal neuropathy in 3 cases [73, 81], and acute motor axonal neuropathy in 1 case [7]. Three patients with GBS presented enhancement of the caudal nerve roots on spine MRI [72, 73]. Sixteen studies reported CSF findings in 22 patients with SARS-CoV-2-related PNS manifestations. The main findings were albuminocytological dissociation with an average of proteins of 96,6 mg/dL, and white cell counts ranging from 0 to 9 cells/ μ L, without other pathologic findings. SARS-CoV-2 tests were negative in all the CSF samples [40, 41, 44, 45, 73, 74, 78–80]. Concomitant *Campylobacter jejuni* infection and Lyme disease were also ruled out [47, 76].

Discussion

To date, this is the most comprehensive systematic review of the central and peripheral involvement of the nervous system by COVID-19 and the only one that integrally assesses the pathophysiology and clinical features, as well as the neuropathology, neuroimaging, electrophysiology, and CSF findings altogether, to analyze their impact in the clinical scenario. Previously reported systematic reviews included a more limited number of articles, ranging between 31 to 37 studies [12, 13]. In many publications, the clinical features and paraclinical findings were siloed and not grouped as nosological entities accounting for neurological involvement of COVID-19.

The specific mechanisms by which SARS-CoV-2 may affect the central nervous system are still debatable. However, there is evidence that combined direct and indirect mechanisms play a role in developing CNS and PNS involvement in patients with COVID-19. This review allowed us to categorize the different pathophysiological processes described below.

Neurotropic properties of SARS-CoV-2

Specific neurologic manifestations are attributable to the neurotropic mechanisms of SARS-CoV-2, which have been demonstrated by electron microscopy, immunohistochemistry, RT-PCR in brain tissue from autopsy specimens, and CSF tests [2, 3, 29, 50, 82]. Propagation can occur through neuronal dissemination, in which the virus would initially infect the PNS and spread until it gains access to the CNS. Anosmia, a frequent symptom in patients with COVID-19, could be an early indication of this pathway [2]. The mechanisms involved may include retrograde or anterograde neuronal transport through the motor proteins dynein and kinesins [83]. SARS-CoV-2 could gain access through the olfactory bulb and the uncinata fasciculus; it would directly reach the anterior cingulate and the basal forebrain [18, 84]. Brainstem involvement can also occur after exposure to human coronaviruses through the nasal cavity [2, 14].

Damage to microvasculature

The spike protein S1 enables the virion's attachment to the angiotensin-converting enzyme 2 (ACE2) receptor, enabling the attachment to the cell membrane [3, 82]. S1 protein in SARS-CoV-2 has 10 to 20 times more affinity for the ACE2 receptor than other coronaviruses. This characteristic might lead to virion's attachment to the cerebral capillary walls after hematogenous dissemination, followed by a distortion of the blood-brain barrier and viral access to the brain tissue [3, 82]. As the virus gains access to cerebral microcirculation, it can create a hypercoagulability state that may slow the cerebral circulation flow, allowing for increased interaction between the virus and the ACE2 receptors [23]. Glial cells, as well as neurons, express ACE2 receptors; therefore, the attachment of the virus to the receptor could contribute to its neurotropism, which, in turn, could initiate a replication cycle with neural cell damage [3, 82].

Brainstem compromise

Animal studies identified the brainstem as a usual target for SARS-CoV. Similarly, cardio-respiratory malfunction in patients with COVID-19 could be due to brainstem impairment by the virus [2, 82, 84]. The brainstem's compromise can also explain other symptoms such as nausea, loss of appetite, and vomiting in COVID 19 patients. Autonomic nervous system dysregulation relates to brainstem regions such as the nucleus of tractus solitarius and the hypothalamus, both part of the dorsal vagal complex. This abnormality may explain nausea, vomiting, and inappetence described in the disease's early stages [21].

Neuroinflammatory response

One way the SAR-CoV-2 can get access to cerebral circulation is by meddling with the immune response. Most of the coronaviruses that affect humans tend to infect the mononuclear phagocytes, leading to the hypothesis that the virus manipulates innate immune response to create a reservoir to access the bloodstream [2, 85]. Endothelial ACE2 receptors' use to attach to the cell can initiate a coagulation cascade, potentially predisposing patients to microthrombi, acute clots, and stroke [18, 82]. Another mechanism from which SARS-CoV-2 can generate brain damage is by creating a secondary encephalopathy due to inflammation or other systemic viral effects [4, 18], such as cerebral hypoxia or immune dysregulation [15]. Furthermore, SARS-CoV-2 can incite proinflammatory cytokines' activation in promoting blood-barrier breakdown, especially IL-8 and monocyte chemoattractant protein-1 [23]. Also, the increase in inflammatory markers can create a local cortical irritation that might initiate seizures [23].

Cytokine storm

SARS-CoV-2 can invade hematopoietic cells and induce a low expression of antiviral cytokines like type I interferon (IFN- $\alpha\beta$) and overexpression of proinflammatory cytokines like TNF- α and IL-6 as well as some chemokines [86]. Besides, a study showed that severe infection by SARS-CoV-2 could create lymphopenia with decreased CD4+ and CD8+, but interestingly, there is no decrease in lymphocytes B. In summary, there is an increase in cytokines IL6, IL2R, IL10, TNF α , and MCP-2 production, and a decrease in IFN- γ production [87]. The resulting cytokine storm can create brain dysfunction and prompt neurological symptoms [5]. In other diseases, inflammatory cytokines passing the blood-brain barrier are a causal mechanism of encephalopathy and a significant systemic inflammatory response that could lead to a cytokine storm with a blood-brain barrier breach [18]. Patients with COVID-19 can also have high levels of IL-8 and IL-10 in CSF [58]. This high cytokine concentration in CSF samples may favor the neuroimmunological theory suggested by several authors, which propose that cytokine-mediated damage could be the leading cause of neurological impairment, rather than direct pathogenicity of the virus on the CNS [7, 20, 35, 61, 88].

Demyelination

Human coronaviruses that infect the CNS can create a chronic infection and progressive demyelination of the brain, similar to multiple sclerosis [2]. The combination of demyelinating lesions and traces of coronavirus in brain tissue from autopsies and in CSF could explain part of the neuronal compromise of SARS-CoV-2 [89].

Systemic hypoxia

Finally, lung infection could establish a state of systemic hypoxia due to the alveolar gas exchange disorders, which could compromise the CNS increasing anaerobic metabolism. Due to this phenomenon, lactic acid accumulation could lead to vasodilation, interstitial edema, obstruction of cerebral blood flow, and even ischemia [83]. Neuropathology findings support this mechanism by describing a hypoxic injury to the cerebrum and cerebellum without associated thrombi or vasculitis [64].

Both the central and the peripheral nervous system may act as a permanent target tissue for neuroinflammatory processes, which has led to theorizing that SARS-CoV-2 infection may trigger or worsen neurodegenerative disorders [86]. COVID-19 infection in children and adolescents may modify long-term cognitive capacities and increase the risk of psychiatric disorders because of the cytokine storm effects in the central nervous system [86]. For COVID-19 survivors with specific neurodegenerative disorders such as Alzheimer's, Parkinson's disease, multiple sclerosis, and mood disorders, a neuroinflammatory component may play a role. Therefore, long-term follow-up of cognitive and psychiatric status should be indicated [86].

Very few publications address the therapeutic approach to CNS and PNS involvement in patients with COVID-19. However, there appears to be consensus on the early recognition and timely treatment of these patients. For instance, delirium requires specific and timely therapeutic measures to decrease its impact on the short- and long-term patient's clinical course [90]. Likewise, the appearance of clinical or subclinical seizures in patients with COVID-19 should prompt starting antiseizure medication since untreated isolated seizures may escalate to non-convulsive status epilepticus, leading to higher morbidity and mortality [33]. Furthermore, a high index of suspicion can lead to early detection and timely treatment of neurological conditions such as stroke, encephalopathy, neuroinflammatory disorders, and peripheral neuropathies.

Limitations

We acknowledge some limitations in this systematic review, including selection bias since our search algorithm included only publications specifically reporting patients with CNS and PNS involvement. Valuable articles with general descriptions of COVID-19 but not explicitly focused on neurological involvement might contain a significant number of patients with neurological manifestations. Besides, most of the scientific evidence available so far originates in observational and descriptive studies. Although we found a significant number of patients with COVID-19 with neurological manifestations, only a small proportion reported neuroimaging, CSF, electrophysiology, and neuropathology findings. This fact might be related to the scarce but ongoing knowledge generated in scientific publications worldwide as the pandemic progresses. International collaborative efforts and exhaustive neurological registries will enhance the translational knowledge of COVID-19's CNS and PNS involvement and generate strategies for therapeutic decision-making [91, 92].

Conclusions

This systematic review presents a comprehensive overview of the scientific literature regarding the central and peripheral nervous system's involvement by COVID-19 and the diverse manifestations in terms of clinical and paraclinical findings. Our synthesis process led to a categorical analysis of the CNS and PNS involvement for all patients included and provided a comprehensive explanation of the reported pathophysiological mechanisms for which SARS-CoV-2 infection may cause neurological impairment. There is a need to conduct prospective cohort studies to analyze the mid and long-term consequences of the CNS and PNS involvement by COVID-19 and randomized clinical trials assessing the efficacy of treatments targeting the neurological compromise by this devastating condition.

List Of Abbreviations

Abbreviation	Meaning
ACE2	Angiotensin-converting enzyme 2
CNS	Central nervous system
COVID-19	Coronavirus disease 2019
CSF	Cerebrospinal fluid
EEG	Electroencephalography
GBS	Guillain-Barré syndrome
GFAP	Glial fibrillary acidic protein
IFN	Interferon
IL	Interleukin
MCP	Monocyte chemoattractant protein
MRI	Magnetic resonance imaging
NFL	Neurofilament light polypeptide
PNS	Peripheral nervous system
PRES	Posterior reversible encephalopathy syndrome
RT-PCR	Reverse transcription polymerase chain reaction
SARS-CoV	Severe acute respiratory syndrome coronavirus
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
TNF	Tumor necrosis factor

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable

Availability of data and material: The dataset supporting the conclusions of this article is available in the Translational Neuroscience Research Lab repository, https://docs.google.com/spreadsheets/d/1OVQg2TRzKOC-YqF_eN2kl7H2iTjnD9Fz7hcU0tPLLUg/edit?usp=sharing

Competing interests: The authors declare that they have no conflict of interest.

Funding: Universidad de La Sabana entirely funded the study and had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Authors' contributions: JIG, LAB, JDM, JPM, and AP participated in the study design, investigation procedures, formal analysis, review, and editing. FES and ZTS participated in the results' formal analysis and the manuscript's

review and editing. KAG conceptualized the original idea and study design, supervised the investigation, methodology, formal analysis, and validation procedures, wrote the original draft, and led the manuscript's review and editing.

Acknowledgments: Not applicable

References

1. WHO. Press Conference: COVID-19 Update (Geneva, 02 October 2020). UN Live United Nations Web TV. 2020. [http://webtv.un.org/search/who-press-conference-covid-19-update-geneva-02-october-2020/6197213072001/?term=who press conference&sort=date](http://webtv.un.org/search/who-press-conference-covid-19-update-geneva-02-october-2020/6197213072001/?term=who+press+conference&sort=date). Accessed October 2, 2020.
2. Acharya A, Kevadiya BD, Gendelman HE, Byrareddy SN. SARS-CoV-2 Infection Leads to Neurological Dysfunction. *J Neuroimmune Pharmacol*. 2020.
3. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chemical Neuroscience*. 2020;11:995–8.
4. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. *Rev Neurol*. 2020;70:311–22.
5. Leonardi M, Padovani A, McArthur JC. Neurological manifestations associated with COVID-19: a review and a call for action. *Journal of Neurology*. 2020;267:1573–6.
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. 2020.
7. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. *JAMA Neurology*. 2020.
8. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. *Lancet Neurol*. 2020;19:767–83. DOI:10.1016/S1474-4422(20)30221-0.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ (Online)*. 2009;339:332–6.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339.
11. Nalleballe K, Reddy Onteddu S, Sharma R, Dandu V, Brown A, Jasti M, et al. Spectrum of neuropsychiatric manifestations in COVID-19. *Brain Behav Immun*. 2020.
12. Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. *Acta Neurologica Scandinavica*. 2020;142:14–22.
13. Munhoz RP, Pedrosa JL, Nascimento FA, Almeida SM de, Barsottini OGP, Cardoso FEC, et al. Neurological complications in patients with SARS-CoV-2 infection: a systematic review. *Arq Neuropsiquiatr*. 2020;78:290–300.
14. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. *Journal of the Neurological Sciences*. 2020;413.
15. Kotfis K, Williams Roberson S, Wilson J, Pun B, Ely EW, Jeżowska I, et al. COVID-19: What do we need to know about ICU delirium during the SARS-CoV-2 pandemic? *Anaesthesiol Intensive Ther*. 2020. doi:10.5114/ait.2020.95164.

16. Mawhinney JA, Wilcock C, Haboubi H, Roshanzamir S. Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode. *BMJ Case Rep.* 2020;13.
17. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun.* 2020.
18. Beach SR, Praschan NC, Hogan C, Dotson S, Merideth F, Kontos N, et al. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. *Gen Hosp Psychiatry.* 2020;65:47–53.
19. Butt I, Sawlani V, Geberhiwot T. Prolonged Confusional state as first manifestation of COVID-19. *Ann Clin Transl Neurol.* 2020.
20. Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. *Journal of Neurology.* 2020.
21. Chigr F, Merzouki M, Najimi M. Autonomic Brain Centers and Pathophysiology of COVID-19. *ACS Chem Neurosci.* 2020.
22. Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, et al. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. *Epilepsia Open.* 2020;5:314–24.
23. Hepburn M, Mullaguri N, George P, Hantus S, Punia V, Bhimraj A, et al. Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association? *Neurocrit Care.* 2020.
24. Morassi M, Bagatto D, Cobelli M, D'Agostini S, Gigli GL, Bnà C, et al. Stroke in patients with SARS-CoV-2 infection: case series. *J Neurol.* 2020.
25. Afshar H, Yassin Z, Kalantari S, Aloosh O, Lotfi T, Moghaddasi M, et al. Evolution and resolution of brain involvement associated with SARS-CoV2 infection: A close Clinical – Paraclinical follow up study of a case. *Mult Scler Relat Disord.* 2020;43.
26. Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, et al. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. *European Journal of Neurology.* 2020.
27. Haddad S, Tayyar R, Risch L, Churchill G, Fares E, Choe M, et al. Encephalopathy and seizure activity in a COVID-19 well controlled HIV patient. *IDCases.* 2020;21.
28. Karimi N, Sharifi Razavi A, Rouhani N. Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report. *Iran Red Crescent Med J.* 2020;22.
29. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis.* 2020;94:55–8.
30. Sohal S, Mansur M. COVID-19 Presenting with Seizures. *IDCases.* 2020;20.
31. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, et al. Focal status epilepticus as unique clinical feature of COVID-19: A case report. *Seizure.* 2020;78:109–12.
32. Le Guennec L, Devianne J, Jalin L, Cao A, Galanaud D, Navarro V, et al. Orbitofrontal involvement in a neuroCOVID-19 patient. *Epilepsia.* 2020;61:e90–4. doi:10.1111/epi.16612.
33. Asadi-Pooya AA. Seizures associated with coronavirus infections. *Seizure.* 2020;79:49–52.
34. Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. New-onset acute symptomatic seizure and risk factors in Corona Virus Disease 2019: A Retrospective Multicenter Study. *Epilepsia.* 2020.

35. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. *Neurology*. 2020;:10.1212/WNL.0000000000009937.
36. Al-olama M, Rashid A, Garozzo D. COVID-19-associated meningoencephalitis complicated with intracranial hemorrhage: a case report. *Acta Neurochir (Wien)*. 2020.
37. Gilani S, Roditi R, Naraghi M. COVID-19 and anosmia in Tehran, Iran. *Med Hypotheses*. 2020;141.
38. Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al. Characteristics of ischaemic stroke associated with COVID-19. *Journal of Neurology, Neurosurgery and Psychiatry*. 2020.
39. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med*. 2020;382:e60.
40. Reyes-Bueno JA, García-Trujillo L, Urbaneja P, Ciano-Petersen NL, Postigo-Pozo MJ, Martínez-Tomás C, et al. Miller-Fisher syndrome after SARS-CoV-2 infection. *Eur J Neurol*. 2020.
41. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. *Neurology*. 2020;:10.1212/WNL.0000000000009619.
42. Falcone MM, Rong AJ, Salazar H, Redick DW, Falcone S, Cavuoto KM. Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19). *J Am Assoc Pediatr Ophthalmol Strabismus*. 2020.
43. Mahammedi A, Saba L, Vagal A, Leali M, Rossi A, Gaskill M, et al. Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study. *Radiology*. 2020; Ss Md:201933.
44. Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. *Neurol Neuroimmunol neuroinflammation*. 2020;7.
45. Goh Y, Beh DLL, Makmur A, Somani J, Chan ACY. Pearls and Oy-sters: Facial nerve palsy as a neurological manifestation of Covid-19 infection. *Neurology*. 2020;:10.1212/WNL.0000000000009863.
46. Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. *J Clin Neurosci*. 2020.
47. Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. *J Peripher Nerv Syst*. 2020; April:2–5.
48. Matos AR, Quintas-Neves M, Oliveira AI, Dias L, Marques S, Carvalho R, et al. COVID-19 associated central nervous system vasculopathy. *Can J Neurol Sci / J Can des Sci Neurol*. 2020;:1–6.
49. Wong PF, Craik S, Newman P, Makan A, Srinivasan K, Crawford E, et al. Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection. *Clin Med*. 2020.
50. Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *Journal of Medical Virology*. 2020;92:699–702.
51. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. *Radiology*. 2020;:201187. doi:10.1148/radiol.2020201187.
52. Kremer S, Lersy F, de Sèze J, Ferré J-C, Maamar A, Carsin-Nicol B, et al. Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. *Radiology*. 2020;:202222. doi:10.1148/radiol.2020202222.
53. Franceschi AM, Ahmed O, Giliberto L, Castillo M. Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection. *Am J Neuroradiol*. 2020.

54. Espinosa PS, Rizvi Z, Sharma P, Hindi F, Filatov A. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, MRI Brain and Cerebrospinal Fluid Findings: Case 2. *Cureus*. 2020.
55. Virhammar J, Kumlien E, Fällmar D, Frithiof R, Jackmann S, Sköld MK, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. *Neurology*. 2020;:10.1212/WNL.0000000000010250.
56. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. *New England Journal of Medicine*. 2020;382:2268–70.
57. Werner C, Scullen T, Mathkour M, Zeoli T, Beighley A, Kilgore MD, et al. Neurological Impact of Coronavirus Disease of 2019: Practical Considerations for the Neuroscience Community. *World Neurosurgery*. 2020;139:344–54.
58. Benameur K, Agarwal A, Auld SC, Butters MP, Webster AS, Ozturk T, et al. Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020. *Emerg Infect Dis*. 2020;26.
59. Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RH. First case of 2019 novel coronavirus disease with encephalitis. *ChinaXiv*. 2020;202003:15.
60. Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. *Brain, Behavior, and Immunity*. 2020.
61. Pilotto A, Odolini S, Stefano Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. Steroid-responsive encephalitis in Covid-19 disease. *Ann Neurol*. 2020.
62. Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, et al. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. *BMC Neurol*. 2020;20.
63. Efe IE, Aydin OU, Alabulut A, Celik O, Aydin K. COVID-19–Associated Encephalitis Mimicking Glial Tumor. *World Neurosurg*. 2020;140:46–8.
64. Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, et al. Neuropathological Features of Covid-19. *N Engl J Med*. 2020. doi:10.1056/NEJMc2019373.
65. Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM). *Journal of Neurology*. 2020.
66. Abdulkadir T, Ünlübaşı Y, Alemdar M, Akyüz E. Coexistence of COVID-19 and acute ischemic stroke report of four cases. *J Clin Neurosci*. 2020.
67. Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S. Cerebral Venous Sinus Thrombosis as a Presentation of COVID-19. *Eur J case reports Intern Med*. 2020;7:001691.
68. Xiong W, Mu J, Guo J, Lu L, Liu D, Luo J, et al. New onset neurologic events in people with COVID-19 infection in three regions in China. *Neurology*. 2020.
69. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. *Acta Neuropathol*. 2020. doi:10.1007/s00401-020-02166-2.
70. Jain R, Young M, Dogra S, Kennedy H, Nguyen V, Jones S, et al. COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. *J Neurol Sci*. 2020;414.
71. Al Saiegh F, Ghosh R, Leibold A, Avery MB, Schmidt RF, Theofanis T, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. *J Neurol Neurosurg Psychiatry*. 2020.

72. Mahammedi A, Luca Saba ;, Vagal A, Leali M, Rossi A, Gaskill M, et al. Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study.
73. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med*. 2020.
74. Ottaviani D, Boso F, Tranquillini E, Gapeni I, Pedrotti G, Cozzio S, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. *Neurol Sci*. 2020;41:1351–4.
75. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *The Lancet Neurology*. 2020;19:383–4.
76. Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain–Barré syndrome. *Rev Neurol (Paris)*. 2020; January.
77. Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? *Journal of Neurology*. 2020.
78. Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, et al. Guillain-Barré syndrome related to COVID-19 infection. *Neurol Neuroimmunol Neuroinflammation*. 2020;7.
79. Chan JL, Ebadi H, Sarna JR. Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection. *Can J Neurol Sci / J Can des Sci Neurol*. 2020;;1–3. doi:10.1017/cjn.2020.106.
80. Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC, Caballo MRB, Garay MH, Celada DR, et al. Guillain–Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection. *Clin Med (Northfield Il)*. 2020;;clinmed.2020-0213.
81. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. *J Clin Neurosci*. 2020;76 January:233–5.
82. Baig AM, Sanders EC. Potential Neuroinvasive Pathways of SARS-CoV-2: Deciphering the Spectrum of Neurological Deficit Seen in Coronavirus Disease 2019 (COVID-19). *J Med Virol*. 2020.
83. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain, Behavior, and Immunity*. 2020.
84. Gandhi S, Srivastava AK, Ray U, Tripathi PP. Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients? *ACS Chem Neurosci*. 2020;11:1379–81.
85. Mankad K, Perry MD, Mirsky DM, Rossi A. COVID-19: A primer for Neuroradiologists. *Neuroradiology*. 2020;62:647–8.
86. Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? *Neurologia*. 2020.
87. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020;130:2620–9.
88. Li H, Xue Q, Xu X. Involvement of the Nervous System in SARS-CoV-2 Infection. *Neurotoxicity Research*. 2020;38.
89. Matías-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu JA. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? *Neurologia*. 2020;35:170–5.
90. Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. *Critical Care*. 2020;24.

91. Román GC, Reis J, Spencer PS, Buguet A, Öztürk S, Wasay M, et al. COVID-19 international neurological registries. *Lancet Neurol.* 2020;19:484–5.
92. The Lancet Neurology TL. The neurological impact of COVID-19. *Lancet Neurol.* 2020;19:471. doi:10.1016/S1474-4422(20)30142-3.